Clinical trials: Behavioral Symptom
Anxiety, Stress
Impact of a Mobile Application (Pacifica) on Stress, Anxiety, and Depression
The study is designed to examine the efficacy of a mobile application implementation of existing best practices in mental health treatment for managing stress, anxiety, and depression.
- Conditions
- Anxiety, Stress, Depression
- Trial name
- NCT03333707
- Testing
- Pacifica App
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Pacifica Labs Inc.
Cardiovascular Disease, Diabetes
Diet and Activity Promotion Among Older Working Adults
The trial will test whether the Alive email-delivered health behavior program can improve subjects' physical activity, fruits and vegetables and saturated/trans fats and added sugars.
- Conditions
- Cardiovascular Disease, Diabetes, Obesity, Aging
- Trial name
- ALIVE (NCT01233063)
- Testing
- Physical Activity and Diet Intervention via Alive2
- Where
- United States
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- Berkeley Analytics, Inc.
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
- Trial name
- NCT01573598
- Testing
- Vilazodone
- Where
- 75 sites in United States, Bulgaria and 6 more
- Volunteers
- 1,219 people
- Sponsor
- Forest Laboratories
Depression
Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression
The primary purpose of this study is to determine if duloxetine plus non-drug intervention is more effective than duloxetine alone in patients with depression.
- Trial name
- NCT00494377
- Testing
- duloxetine
- Where
- Austria
- Volunteers
- 940 people
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy Subjects
To evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of GW117 ODT in healthy volunteers
- Trial name
- NCT06964711
- Testing
- GW117 ODT
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Beijing Greatway Pharmaceutical Technology Co.,Ltd.
Huntington's Disease
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease.
- Trial name
- NCT02197130
- Testing
- PF-02545920
- Where
- 57 sites in United States, Canada and 3 more
- Volunteers
- 272 people
- Sponsor
- Pfizer
Melanoma
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC) SC and provide patient experience data by route of administration.
- Trial name
- NCT06101134
- Testing
- relatlimab+nivolumab, relatlimab+nivolumab+rHuPH20, nivolumab
- Where
- 31 sites in United States, Chile and 3 more
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Depressive Episodes, Bipolar I Depression
A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression).
- Trial name
- NCT05227209
- Testing
- SEP-4199 CR
- Where
- 69 sites in United States, Bulgaria and 1 more
- Volunteers
- 64 people
- Sponsor
- Sumitomo Pharma America, Inc.
Oral Mucositis, Quality of Life
Effect of a Novel Topical Composition on the Incidence of Severe Oral Mucositis in Head & Neck Cancer Radiated Patients and Quality of Life Assessed by PROMs.
The use of a novel topical mucosa composition (XCM-OM118) comprising 2-(trimethylazaniumyl) acetate; (2R,3R,4S)-pentane-1,2,3,4,5-pentol; Hexadecanoic acid; (9Z, 12Z)-octadeca-9,12-dienoic acid; octadecanoic acid…
- Conditions
- Oral Mucositis, Quality of Life, Mucositis, Pain
- Trial name
- STOPOMP (NCT05635929)
- Testing
- XCM-OM118 Composition comprising olive oil, betaine and xylitol
- Where
- Spain
- Volunteers
- 63 people
- Sponsor
- Mucosa Innovations, S.L.
Obesity, Overweight and Obesity
Improving Quality of Life in Men and Women With Overweight or Obesity
The purpose of this study is to evaluate the effect of the Noom Healthy Weight Program, a digital behavior change weight loss intervention, on quality of life as measured both by self-report and objective measures, compared to a…
- Conditions
- Obesity, Overweight and Obesity, Quality of Life, Health Behavior
- Trial name
- NCT04871295
- Testing
- Noom Healthy Weight
- Where
- United States
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
COPD
Study to Evaluate the Impact of the "PROactive Telecoaching Program" on Physical Activity in Patients With COPD.
This study will test two instruments to measure physical activity in COPD patients: A questionnaire and two small physical activity monitors .Patients will be randomized to either receive the telecoaching program in addition to…
- Trial name
- PROactive (NCT01992081)
- Testing
- Automated telehealth system, Usual care
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Renal Cell
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
Information on the prevalence of advanced/metastatic renal cell carcinoma and its symptom burden is limited in commercially insured adult patients.
- Trial name
- NCT01381601
- Testing
- Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Adjunctive Treatment of Major Depressive Disorder (MDD)
A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder
The study is a Phase 2, double-blind, randomized, placebo-controlled study in Major Depressive Disorder (MDD) participants with an inadequate response to standard antidepressants The objective of the study is to assess CLE-100…
- Trial name
- SOLEO (NCT06340958)
- Testing
- CLE-100
- Where
- 23 sites in United States
- Volunteers
- 99 people
- Sponsor
- Clexio Biosciences Ltd.
Sexual Dysfunctions, Psychological, Depression
12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress
The current trial will explore the safety of flibanserin in combination with Selective Serotonin Reuptake Inhibitors or Norepinephrine Serotonin Reuptake Inhibitors in a representative population of women with depressive and…
- Trial name
- NCT01040208
- Testing
- flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs
- Where
- 42 sites in United States
- Volunteers
- 111 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Unipolar Depression, Major Depressive Disorder (MDD)
Validation of EmoDTx as a Digital Endpoint for Mood Monitoring in Adult Patients Suffering From Unipolar Depression
The aim of this study is to validate the EmoDTx as a digital tool for mood monitoring in adult patients with unipolar depression. The study is prospective, multicenter, and observational, with a single-arm approach.
- Conditions
- Unipolar Depression, Major Depressive Disorder (MDD), Depression
- Trial name
- EMC2FR (NCT06860165)
- Where
- 2 sites in France
- Volunteers
- 98 people
- Sponsor
- Emobot
Erythema, Skin Recovery
A Study to Gain Information How Well Dexpanthenol Derma Cream Helps the Face Skin to Recover After Cosmetic Lasering
In this study, researchers want to learn more about the effect of dexpanthenol cream on skin recovery and reduction of skin rash after a dermatological procedure (ablative laser) on the face for treatment of fine wrinkles, scars…
- Trial name
- NCT03852563
- Testing
- BAY207543 (Bepanthol), Semisolid vaseline
- Where
- Brazil
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Bayer
Major Depressive Disorder
Ketamine for Major Depressive Disorder
The purpose of this study is to measure the amount of ketamine in blood over time in subjects diagnosed with Major Depressive Disorder (MDD) and explore the anti-depressive effects of ketamine delivered by transdermal patch.
- Trial name
- NCT03721900
- Testing
- SHX-001 Active low dose, SHX-001 Active High dose
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shenox Pharmaceuticals, LLC
Bipolar Depression
Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression
The primary purpose of this study is to determine the safety and efficacy of oral RG2417 (Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.
- Trial name
- NCT00322764
- Testing
- Uridine
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Repligen Corporation
Depression
A Mobile and Virtual Reality Intervention for Adolescent Depression
Depression, the most common mental health disorder among adolescents, is a critical health problem within the US. In this study, the feasibility, acceptability, and preliminary efficacy of Limbix Spark, a cognitive behavioral…
- Trial name
- NCT04165681
- Testing
- Limbix Spark
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Limbix Health, Inc.
Depression, Bipolar I Disorder
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States.
- Trial name
- 3112 Ped BPD (NCT04777357)
- Testing
- Cariprazine
- Where
- 81 sites in United States, Puerto Rico and 1 more
- Volunteers
- 380 people
- Sponsor
- AbbVie